
Cybele C Garcia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5473742/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of Chemical and Antiviral Properties of Essential Oils from South American Plants. Antiviral Chemistry and Chemotherapy, 2005, 16, 247-251.	0.6	70
2	AHR is a Zika virus host factor and a candidate target for antiviral therapy. Nature Neuroscience, 2020, 23, 939-951.	14.8	57
3	Inhibitory Effect of Thiosemicarbazone Derivatives on Junin Virus Replication <i>In Vitro</i> . Antiviral Chemistry and Chemotherapy, 2003, 14, 99-105.	0.6	44
4	Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. Journal of General Virology, 2006, 87, 1217-1228.	2.9	40
5	Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral Research, 2012, 93, 16-22.	4.1	40
6	ARâ€12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication. Journal of Cellular Physiology, 2016, 231, 2286-2302.	4.1	38
7	AHR signaling is induced by infection with coronaviruses. Nature Communications, 2021, 12, 5148.	12.8	38
8	Dengue virus targets RBM10 deregulating host cell splicing and innate immune response. Nucleic Acids Research, 2020, 48, 6824-6838.	14.5	37
9	Lymphocytic choriomeningitis virus (LCMV) infection of macaques: A model for Lassa fever. Antiviral Research, 2011, 92, 125-138.	4.1	36
10	Cellular Promyelocytic Leukemia Protein Is an Important Dengue Virus Restriction Factor. PLoS ONE, 2015, 10, e0125690.	2.5	30
11	Synthesis and Evaluation of <i>N</i> -Substituted Acridones as Antiviral Agents against Haemorrhagic Fever Viruses. Antiviral Chemistry and Chemotherapy, 2008, 19, 41-47.	0.6	29
12	Host Cell Factors as Antiviral Targets in Arenavirus Infection. Viruses, 2012, 4, 1569-1591.	3.3	26
13	Antiviral activity of A771726, the active metabolite of leflunomide, against JunÃn virus. Journal of Medical Virology, 2018, 90, 819-827.	5.0	25
14	Inhibition of JunÃn virus replication by small interfering RNAs. Antiviral Research, 2009, 84, 31-37.	4.1	24
15	Cellular Organelles Reorganization During Zika Virus Infection of Human Cells. Frontiers in Microbiology, 2020, 11, 1558.	3.5	23
16	The interplay between viperin antiviral activity, lipid droplets and JunÃn mammarenavirus multiplication. Virology, 2018, 514, 216-229.	2.4	21
17	De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus. European Journal of Medicinal Chemistry, 2019, 182, 111628.	5.5	20
18	Advances in drug delivery, gene delivery and therapeutic agents based on dendritic materials. Future Medicinal Chemistry, 2019, 11, 1791-1810.	2.3	19

CYBELE C GARCIA

#	Article	IF	CITATIONS
19	Dengue Non-structural Protein 5 Polymerase Complexes With Promyelocytic Leukemia Protein (PML) Isoforms III and IV to Disrupt PML-Nuclear Bodies in Infected Cells. Frontiers in Cellular and Infection Microbiology, 2019, 9, 284.	3.9	19
20	Characterization of JunÃn virus particles inactivated by a zinc finger-reactive compound. Virus Research, 2009, 143, 106-113.	2.2	18
21	Antiviral activity of an N-allyl acridone against dengue virus. Journal of Biomedical Science, 2015, 22, 29.	7.0	18
22	Novel therapeutic targets for arenavirus hemorrhagic fevers. Future Virology, 2011, 6, 27-44.	1.8	15
23	Inhibition of arenavirus infection by thiuram and aromatic disulfides. Antiviral Research, 2010, 87, 329-337.	4.1	14
24	Zika virus infection of first trimester trophoblast cells affects cell migration, metabolism and immune homeostasis control. Journal of Cellular Physiology, 2021, 236, 4913-4925.	4.1	12
25	Antiviral bioactivity of resveratrol against Zika virus infection in human retinal pigment epithelial cells. Molecular Biology Reports, 2021, 48, 5379-5392.	2.3	12
26	Antiviral activity against Zika virus of a new formulation of curcumin in poly lactic- <i>co</i> -glycolic acid nanoparticles. Journal of Pharmacy and Pharmacology, 2021, 73, 357-365.	2.4	11
27	Differential inhibitory action of two azoic compounds against arenaviruses. International Journal of Antimicrobial Agents, 2003, 21, 319-324.	2.5	10
28	Virucidal Activity and Chemical Composition of Essential Oils from Aromatic Plants of Central West Argentina. Natural Product Communications, 2010, 5, 1934578X1000500.	0.5	9
29	Synthesis and antiviral evaluation of some carbonucleoside analogues. Journal of Heterocyclic Chemistry, 2005, 42, 979-983.	2.6	7
30	Targeting of Arenavirus RNA Synthesis by a Carboxamide-Derivatized Aromatic Disulfide with Virucidal Activity. PLoS ONE, 2013, 8, e81251.	2.5	7
31	Towards Host Cell-Targeting Therapies to Treat Dengue Virus Infections. Frontiers in Anti-infective Drug Discovery, 2018, , 45-87.	0.6	6
32	Determining the Virus Life-Cycle Stage Blocked by an Antiviral. Methods in Molecular Biology, 2018, 1604, 371-392.	0.9	3
33	Synthesis and Antibacterial Activity of Difluoromethyl Cinnamoyl Amides. Molecules, 2020, 25, 789.	3.8	2
34	Progress for Antiviral Development in Latin America. , 2017, , 439-460.		2
35	Promyelocytic leukemia protein is a restriction factor for JunÃn virus independently of Z matrix protein. Biochemical and Biophysical Research Communications, 2022, 606, 168-173.	2.1	1

Perspectives for the Therapy against Arenavirus Infections. , 2005, , 115-138.

0

CYBELE C GARCIA

#	Article	IF	CITATIONS
37	How do host restriction factors influence dengue virus replication?. Future Virology, 2016, 11, 757-760.	1.8	0
38	Identifying Restriction Factors for Hemorrhagic Fever Viruses: Dengue and JunÃn. Methods in Molecular Biology, 2018, 1604, 351-370.	0.9	0
39	Arenaviruses. , 2020, , .		Ο